Rhumbline Advisers Rocket Pharmaceuticals, Inc. Transaction History
Rhumbline Advisers
- $104 Billion
- Q1 2025
A detailed history of Rhumbline Advisers transactions in Rocket Pharmaceuticals, Inc. stock. As of the latest transaction made, Rhumbline Advisers holds 107,638 shares of RCKT stock, worth $844,958. This represents 0.0% of its overall portfolio holdings.
Number of Shares
107,638
Previous 99,339
8.35%
Holding current value
$844,958
Previous $1.25 Million
34.62%
% of portfolio
0.0%
Previous 0.0%
Shares
28 transactions
Others Institutions Holding RCKT
# of Institutions
243Shares Held
94.8MCall Options Held
262KPut Options Held
159K-
Rtw Investments, LP New York, NY17.7MShares$139 Million3.63% of portfolio
-
Vanguard Group Inc Valley Forge, PA6.58MShares$51.6 Million0.0% of portfolio
-
Black Rock Inc. New York, NY6.19MShares$48.6 Million0.0% of portfolio
-
Lee Ainslie Maverick Capital LTD | Dallas, Tx5.2MShares$40.8 Million1.26% of portfolio
-
Westfield Capital Management CO LP Boston, MA4.71MShares$37 Million0.27% of portfolio
About ROCKET PHARMACEUTICALS, INC.
- Ticker RCKT
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 75,683,696
- Market Cap $594M
- Description
- Rocket Pharmaceuticals, Inc., together with its subsidiaries, operates as a multi-platform biotechnology company that focuses on developing gene therapies for rare and devastating diseases. It has three clinical-stage ex vivo lentiviral vector programs for fanconi anemia, a genetic defect in the bone marrow that reduces production of blood cells...